CAS NO: | 1282512-48-4 |
生物活性 | Taselisib (GDC-0032) is a potentPI3Kinhibitor targets PIK3CA mutations, withKis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM forPI3Kδ,PI3Kα,PI3KγandPI3Kβ, respectively. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | Taselisib (GDC-0032) (100 nM) inhibits AKT/mTOR signaling in PIK3CA mutant cell lines but not in cells with loss or mutation of PTEN; Taselisib (GDC-0032) enhances radiation-induced apoptosis and inhibits growth in head and neck cancer cell lines that are sensitive to its single-agent activiy[1]. Taselisib (GDC-0032) enhances the effects of MEK1/2 inhibition on both BRAFV600E/PTENNullhuman melanoma cells autochthonous mouse melanomas[2]. | ||||||||||||||||
体内研究 (In Vivo) | Taselisib (GDC-0032) (5 mg/kg, p.o.) potently impairs PI3K signaling and enhances the efficacy of fractionated radiotherapy; Taselisib (GDC-0032) and radiation is more effective than either treatment alone in nude mice implanted with subcutaneous Cal-33 xenografts[1]. The vehicle-treated BRAFV600E/PTENNull melanoma-bearing mice experiencs initial tumor regression after treatment with Taselisib (GDC-0032) (22.5 mg/kg, p.o.)[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 460.53 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H28N8O2 | ||||||||||||||||
CAS 号 | 1282512-48-4 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(54.29 mM;ultrasonic and warming and heat to 60℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2025 |